AVALO THERAPEUTICS INC (AVTX) — insider trading
Health Care · NASDAQ
AVALO THERAPEUTICS INC (AVTX) has 17 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 17 (latest 2026-06-30).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Jain Rita | Director | Grant / award / vesting (derivative) | 1,080 | $15.04 | $16.2K | Form 4 |
| 2026-06-30 | Lind Kevin Robert | Director | Grant / award / vesting (derivative) | 1,105 | $15.04 | $16.6K | Form 4 |
| 2026-06-30 | Philip Ron M | Director | Grant / award / vesting (derivative) | 69 | $15.04 | $1.0K | Form 4 |
| 2026-06-30 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 1,779 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 2,875 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 4,654 | $20.00 | $93.1K | Form 4 |
| 2026-06-30 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 1,779 | $8.04 | $14.3K | Form 4 |
| 2026-06-30 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 2,875 | $12.65 | $36.4K | Form 4 |
| 2026-06-23 | Philip Ron M | Director | Grant / award / vesting (derivative) | 40,200 | $0.00 | $0 | Form 4 |
| 2026-06-23 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 1,450 | $0.00 | $0 | Form 4 |
| 2026-06-23 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 1,450 | $18.00 | $26.1K | Form 4 |
| 2026-06-23 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 1,450 | $8.04 | $11.7K | Form 4 |
| 2026-06-10 | Doyle Mittie | Officer (Chief Medical Officer) | Shares withheld for taxes / exercise cost | 1,084 | $13.10 | $14.2K | Form 4 |
| 2026-06-10 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 138 | $13.10 | $1.8K | Form 4 |
| 2026-06-10 | VARKI PAUL | Officer (Chief Legal Officer) | Shares withheld for taxes / exercise cost | 1,081 | $13.10 | $14.2K | Form 4 |
| 2026-06-10 | Riley Jennifer | Officer (Chief Strategy Officer) | Shares withheld for taxes / exercise cost | 588 | $13.10 | $7.7K | Form 4 |
| 2026-06-02 | Lind Kevin Robert | Director | Grant / award / vesting (derivative) | 20,100 | $0.00 | $0 | Form 4 |
Ask the chat about AVTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: AVALO THERAPEUTICS INC (AVTX).
Last updated 2026-06-30 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.